• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

我父亲肺鳞癌的治疗贴(2014年3月1日驾鹤西去)

    [复制链接]
1246941 1620 老马 发表于 2011-10-27 08:05:18 | 置顶 |
老马  博士一年级 发表于 2012-4-27 18:50:42 | 显示全部楼层 来自: 浙江温州
Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type! y0 o! p5 I4 F, d5 R4 ]) y
NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9
  {8 B9 p! S% H9 I+ k" z' T+ Author Affiliations% B; D+ j9 s, h7 s2 d

0 Y9 ^$ j# i( @; I! r6 `/ Y3 |1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan
3 N. T8 E8 F0 V1 j3 @2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan 9 ^% Z; }3 ^2 f. ?$ K, T
3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
) X0 o, X! m9 {: Q4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
( N  E  e9 Q  C* v5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan ) z% P/ |- k& l( u( r3 i
6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
- |9 G7 g% i/ i7Kinki University School of Medicine, Osaka 589-8511, Japan - t- |9 c3 _' D/ S* H( j" B" [
8Izumi Municipal Hospital, Osaka 594-0071, Japan
7 b3 v3 Y. j5 \+ ~9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
- E* ]1 X6 a+ K, D! `2 g5 D3 M$ GCorrespondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp
$ o& s3 s) ]8 G3 t* M9 o0 [! VAbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type. 1 i6 n& C6 W+ P6 m6 l

3 |6 P+ O! i0 A+ F( v4 x
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:52:43 | 显示全部楼层 来自: 浙江温州
S-1 monotherapy for previously treated non-small cell lung cancer: A retrospective analysis by age and histopathological type
( b+ V3 @8 {3 @# |* z  a
: {( a. e3 t1 W! e+ `9 ^, QAuthors: Yuki Tomita, Tetsuya Oguri, Osamu Takakuwa, Makoto Nakao, Eiji Kunii, Takehiro  Uemura, Hiroaki Ozasa, Mikinori Miyazaki, Ken Maeno, Shigeki Sato
1 n( \. M; G4 o$ {! A' w8 m" b0 V) P. \
Affiliations: Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601, Japan  
$ P! `8 T2 x6 ?9 i
5 I6 l' T9 R% j1 @, Y* hPublished online on: Thursday, December 1, 2011
. B, Q! H2 t. C) N% F$ r; ^+ q9 y5 K: A1 t
Doi: 10.3892/ol.2011.507 + U: C1 \$ M2 D% X9 L" u& f

: ~& G) a6 I' D# ?9 CPages: 405-410 3 w: e+ _! U7 s+ ]

3 H5 B8 e# W. C7 mAbstract:1 O1 ~1 _7 H3 B" m
S-1, an oral fluoropyrimidine derivative, has been approved for the treatment of non-small cell lung cancer (NSCLC) in Japan. In the present study, the efficacy and safety of S-1 monotherapy for elderly patients with previously treated NSCLC were retrospectively evaluated, and the efficacy of S-1 monotherapy was compared by histopathological type. This retrospective study included 54 patients with advanced or recurrent NSCLC who had received S-1 monotherapy following the failure of previous chemotherapy regimens at our institutes. Patient outcomes were compared based on their age and histopathological type. S-1 was administered orally, twice daily, while the duration and interval were modified according to the medical condition of each patient. The default delivery schedule, the mean number of S-1 cycles, did not differ significantly between the two age groups (<70 and ≥70 years). The rate of therapy discontinuation, schedule modification or dose reduction due to intolerable toxicities or patient refusal was relatively frequent in the older group (40.7 and 55.6% for ages <70 and ≥70 years, respectively; p=0.414), and the incidence of grade 3 anemia was relatively high in the older group (3.7 and 18.5%, respectively; p=0.192). The response rates (13.0 and 4.8%, respectively; p=0.609) and disease control rates (39.1 and 33.3%, respectively; p=0.761) did not differ significantly between the two age groups. According to histopathological type, the disease control rate was significantly higher in adenocarcinoma (57.9%) compared to non-adenocarcinoma (20.0%, p=0.013). Thus, S-1 monotherapy may be equally effective and tolerated in patients <70 years and those ≥70 years. Additionally, adenocarcinoma may have a higher disease control rate than non-adenocarcinoma.
" p# M& L3 h# z& F' k . v" S7 {3 J1 s* L. n
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:57:27 | 显示全部楼层 来自: 浙江温州
Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population
& W: ?9 Y# M. gF. Tanaka1,*, H. Wada2, Y. Fukui3 and M. Fukushima3
5 n; n, `; F& t% D" d1 i6 Y7 x+ Author Affiliations
! e3 [' S$ X% r+ a) l+ Y) u1Second Department of Surgery, University of Environmental and Occupational Health, Kitakakyushu # d9 Q" `3 x2 q" ]3 B+ C* M
2Department of Thoracic Surgery, Kyoto University, Kyoto . U  L' ?  A. Z2 R
3Tokushima Research Center, Taiho Pharmaceutical Co. Ltd, Tokushima, Japan
! i! P& U* q$ d, J1 c&#8629;*Correspondence to: Dr F. Tanaka, Second Department of Surgery, University of Environmental and Occupational Health, 1-1 Isegaoka, Yahata-nishi, Kitakakyushu, 807-8555, Japan. Tel: +81-93-891-7442; Fax: +81-93-692-4004; E-mail: ftanaka@med.uoeh-u.ac.jp
* w  S& U& i. ~4 s7 x$ j5 EReceived September 3, 2010.
% @& [  d3 X) v$ B8 [Revision received November 11, 2010.
& R5 r, `, |: d; p7 c; e2 L0 t! f; EAccepted November 17, 2010.
) o( \0 Y# E5 x" a) s$ VAbstract
! H" U) ]7 [1 ~' O5 M1 U2 QBackground: Previous small-sized studies showed lower thymidylate synthase (TS) expression in adenocarcinoma of the lung, which may explain higher antitumor activity of TS-inhibiting agents such as pemetrexed. 2 G- k/ a6 \& m5 D& ]/ w
Patients and methods: To quantitatively measure TS gene expression in a large-scale Japanese population (n = 2621) with primary lung cancer, laser-captured microdissected sections were cut from primary tumors, surrounding normal lung tissues and involved nodes.
" j2 d% j5 ]: H+ mResults: TS gene expression level in primary tumor was significantly higher than that in normal lung tissue (mean TS/β-actin, 3.4 and 1.0, respectively; P < 0.01), and TS gene expression level was further higher in involved node (mean TS/β-actin, 7.7; P < 0.01). Analyses of TS gene expression levels in primary tumor according to histologic cell type revealed that small-cell carcinoma showed highest TS expression (mean TS/β-actin, 13.8) and that squamous cell carcinoma showed higher TS expression as compared with adenocarcinoma (mean TS/β-actin, 4.3 and 2.3, respectively; P < 0.01); TS gene expression was significantly increased along with a decrease in the grade of tumor cell differentiation. There was no significant difference in TS gene expression according to any other patient characteristics including tumor progression. : s4 Z7 {, F( ?# T! @$ k9 K  r
Conclusion: Lower TS expression in adenocarcinoma of the lung was confirmed in a large-scale study. 5 m+ j# w2 b/ |: |, z( g4 D
个人公众号:treeofhope
走在异乡  高中一年级 发表于 2012-4-28 00:30:22 | 显示全部楼层 来自: 四川成都
一直关注老马的帖子,前方的指明灯。祝福你爸好疗效
累计签到:1 天
连续签到:1 天
[LV.1]初来乍到
baiselianyi  初中二年级 发表于 2012-4-28 10:24:44 | 显示全部楼层 来自: 浙江台州
一直得到老马帮助,祝福老马爸爸
老马  博士一年级 发表于 2012-4-28 18:00:37 | 显示全部楼层 来自: 浙江温州
26日吃了12片地米(0.75mg一片),27日吃了22片地米(0.75mg 一片),28日吃了12片地米(0.75mg一片),都分二次吃。
) q" T; o% l9 d) ]& A0 [今天为止没有任何反应,每天吃VC,VB2,还有漱口水,就怕口腔溃疡。
个人公众号:treeofhope
bishop_cn  大学一年级 发表于 2012-4-28 23:16:11 | 显示全部楼层 来自: 中国
副作用如何,单药反应很小吧?
# Q1 U! l# ]+ f
老马  博士一年级 发表于 2012-4-29 00:20:00 | 显示全部楼层 来自: 浙江温州
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy
' M4 }6 e4 \) t2 Z6 f$ chttp://clinicaltrials.gov/ct2/show/NCT015235878 U) P4 g# ]% e0 ]5 d
' z: Z2 d/ I3 [
BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC
' f# ^# I1 _+ }! C1 chttp://clinicaltrials.gov/ct2/show/NCT01156545
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-29 20:53:58 | 显示全部楼层 来自: 浙江温州
本帖最后由 老马 于 2012-4-30 09:33 编辑
9 q( g6 O: E3 i' l2 U6 l+ ^2 S
, x- N& P+ N6 g6 ?3 U7 B, v从4月24日开始到4月28日,打了5天的舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。
: e7 @& X) K/ w- G$ V+ w至今为止,未出现化疗副作用。
个人公众号:treeofhope
英雄武松  大学四年级 发表于 2012-4-30 01:37:05 | 显示全部楼层 来自: 哈萨克斯坦
老马 发表于 2012-4-29 20:53 ( C9 ~! {' x; j9 \0 U* t
从4月24日开始到4月28日,打了5天的打了5天舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。- q! Q  G! j  i9 F* y
至今为止,未出 ...
) e& P* I. d2 R; ~
没有副作用是第一追求,效果显著是第二追求。
6 ^: T6 e7 V! I; i( Q* L0 I% g& g不错。

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表